Company intelligence / Profile preview
Engitix Therapeutics
London, England, United Kingdomengitix.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Engitix has developed a proprietary human ECM-based drug discovery platform that enables identification of novel therapeutic targets for fibrosis and solid tumors. The company has several preclinical programs targeting both intracellular and extracellular mechanisms driving these diseases. Its most advanced internal candidates are expected to enter clinical trials around or after 2025. The company also has major partnered programs with Takeda in liver fibrosis/NASH/IBD and with Dompé Farmaceutici in liver-associated cancers/fibrosis.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small moleculesAntibodiesOther biologics (based on ECM platform outputs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceuticals — multi-program collaborations/licensing for liver fibrosis, NASH/MASH, IBD worth over $500 million+ biodollarsDompé Farmaceutici — strategic R&D collaboration/investment for precision medicines against fibrosis/liver cancer using AI-driven Exscalate platformMorphic Therapeutics — partnership for ECM-related target ID in IBD
Beyond the preview
Go deeper on Engitix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engitix Therapeutics.